Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PRESS RELEASE: CureVac Appoints Klaus Edvardsen as Chief Development Officer

06/02/2021 | 07:02am EDT
DGAP-News: CureVac / Key word(s): Personnel 
CureVac Appoints Klaus Edvardsen as Chief Development Officer 
2021-06-02 / 13:00 
The issuer is solely responsible for the content of this announcement. 
CureVac Appoints Klaus Edvardsen as Chief Development Officer 
TÜBINGEN, Germany / BOSTON, USA - June 2, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical 
company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today 
announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer. The appointment of Dr. Edvardsen 
will take effect on August 1, 2021. 
"We are very happy to welcome Dr. Edvardsen to the CureVac leadership team," said Jean Stéphenne, Chairman of the 
Supervisory Board of CureVac. "He has a tremendous background, having led both business development and clinical 
research on a global scale for several high-profile biopharmaceutical companies. His great breadth of knowledge and 
expertise in research and different therapeutic areas will serve CureVac well as it continues to evolve from a 
research-oriented biotechnology to a fully integrated biopharmaceutical company." 
"We are very pleased that Klaus is joining us in highly dynamic times for the company," said Dr. Franz-Werner Haas, 
Chief Executive Officer of CureVac. "He brings a wealth of experience in both clinical development and product 
development, with a specific focus on oncology and therapies. Looking ahead, his expertise will be of great value to us 
as we expand our pipeline, advance our technology platform and further grow our company." 
"I am both honored and excited to be joining CureVac at such an interesting point in its growth journey," said Dr. 
Edvardsen. "Their years of dedicated work on mRNA therapeutics positions CureVac well for bringing future treatments 
across a variety of indications to different patient populations. I am looking forward to contributing my experiences 
to the company and its development programs." 
Dr. Edvardsen joins CureVac from Merck KGaA, where he led early- and late-stage global oncology development as a Senior 
Vice President and Head of Global Oncology Development. He served at AstraZeneca prior to that, as Senior Vice 
President and Head of Global Medicines Development Oncology, where he was responsible for the overall development 
strategy for oncology and hematology programs. Dr. Edvardsen also held leadership roles at both GlaxoSmithKline PLC and 
at Genmab A/S in medicines development within various therapeutic areas. 
Dr. Edvardsen's previous research work includes several positions as adjunct member and professor in oncology at 
various institutes in Denmark, USA, Norway and Sweden. Dr. Edvardsen holds a MD degree as well as a PhD in cancer 
biology from University of Copenhagen. 
About CVnCoV 
CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen for 
first clinical development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized 
full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 and 2a 
clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November 
2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in 
addition to first indication of T cell activation. The quality of the immune response was comparable to recovered 
COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. In December 2020, CureVac 
initiated a pivotal Phase 2b/3, the HERALD study, with a 12µg dose of CVnCoV. In February 2021, CureVac initiated a 
rolling submission with the European Medicines Agency (EMA) for CVnCoV. 
About CureVac 
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years 
of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of 
CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human 
body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, 
the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody 
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 
2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, 
and Boston, USA. Further information can be found at www.curevac.com. 
CureVac Media Contact 
Anna Kamilli, Manager Communications 
CureVac, Tübingen, Germany 
T: +49 7071 9883-1684 
Bettina Jödicke-Braas, Manager Communications 
CureVac, Tübingen, Germany 
T: +49 7071 9883-1087 
CureVac Investor Relations Contact 
Dr. Sarah Fakih, Vice President Investor Relations 
CureVac, Tübingen, Germany 
T: +49 7071 9883-1298 
M: +49 160 90 496949 
Forward-Looking Statements 
This press release contains statements that constitute "forward looking statements" as that term is defined in the 
United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, 
expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned 
subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc. and CureVac Swiss AG (the "company") regarding future 
events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the 
potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, 
growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology 
such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," 
"could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking 
statements are based on management's current beliefs and assumptions and on information currently available to the 
company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not 
place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other 
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the 
worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and 
clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and 
collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in 
current and proposed legislation, regulations and governmental policies, pressures from increasing competition and 
consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of 
operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability 
to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other 
factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place 
undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual 
results to differ materially from those it thought would occur. The forward-looking statements included in this press 
release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation 
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect 
future events or developments, except as required by law. 
For further information, please reference the company's reports and documents filed with the U.S. Securities and 
Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. 
2021-06-02 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:     English 
Company:      CureVac 
              Friedrich-Miescher-Str. 15 
              72076 Tübingen 
EQS News ID:  1203678 
End of News   DGAP News Service 

1203678 2021-06-02

Image link: 

(END) Dow Jones Newswires

June 02, 2021 07:01 ET (11:01 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ACTIVATION GROUP HOLDINGS LIMITED -1.22% 0.81 End-of-day quote.5.19%
ASTRAZENECA PLC -0.11% 8268 Delayed Quote.13.01%
CUREVAC N.V. -5.07% 49.23 Delayed Quote.-36.03%
DJ INDUSTRIAL -0.39% 34942.89 Delayed Quote.14.13%
GENMAB A/S 1.14% 2835 Delayed Quote.13.80%
GLAXOSMITHKLINE PLC 0.81% 1417.8 Delayed Quote.4.80%
MERCK KGAA 0.23% 172.65 Delayed Quote.22.73%
NASDAQ COMP. -0.70% 14677.176315 Real-time Quote.14.54%
All news about CUREVAC N.V.
07/20EU begins real-time review of Sanofi-GSK COVID-19 vaccine
07/05S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
07/04S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
07/01SECTOR UPDATE : Health Care Stocks Post Solid Gains Thursday
07/01SECTOR UPDATE : Health Care Stocks Outpacing Most Other Sectors This Afternoon
07/01GLOBAL MARKETS LIVE : Amazon, The Gap, Fod, Lockheed Martin, CureVac...
07/01SECTOR UPDATE : Health Care Stocks Steady Premarket Thursday
07/01Wall Street Sees Narrowly Mixed Open; Weekly Jobless Claims Fall
07/01EUROPEAN MIDDAY BRIEFING : Stocks Jump to Open -2-
More news
Sales 2021 486 M 576 M 576 M
Net income 2021 341 M 404 M 404 M
Net cash 2021 2 745 M 3 256 M 3 256 M
P/E ratio 2021 15,6x
Yield 2021 -
Capitalization 18 080 M 21 497 M 21 446 M
EV / Sales 2021 31,6x
EV / Sales 2022 3,04x
Nbr of Employees 505
Free-Float 44,1%
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 43,62 €
Average target price 63,03 €
Spread / Average Target 44,5%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-36.03%21 497
MODERNA, INC.230.85%138 784
LONZA GROUP AG21.77%56 806
CELLTRION, INC.-27.16%31 282
SEAGEN INC.-12.38%26 668